Abstract: Liquid amine terminated polyamide addition products having an average molecular weight of about 3,000 to about 10,000 are prepared by the non-catalytic reaction of a dicarboxylic acid having a molecular weight within the range of about 130 to about 700 with a higher molecular weight polyoxypropylene diamine having an average molecular weight within the range of about 1,500 to about 6,000 and with a lower molecular weight polyoxypropylene diamine having an average molecular weight within the range of about 200 to about 700, the reaction conditions including a temperature within the range of about 150.degree. to about 280.degree. C., a pressure of about 0.1 to 20 atmospheres and a reaction time of about 2 to about 5 hours.

Abstract: A method of preparing a cell block for cytological examination of cellular material such as fine needle aspirate material comprises depositing gel medium, preferably an algin medium, and sample material in an enclosure defined by a support web, and then causing the gel medium to set to form a button that can be subjected to processing routines to produce a processed button embeddable in embedding medium. The gel medium and the sample material are preferably codeposited in the enclosure by centrifugation, the support web being prewetted with a setting agent for the gel medium.A carrier that serves to support the support web during deposition and that is foldable to form a processing cassette for the deposited and set button is also disclosed.

Abstract: We describe the use of phospholipidic carnitine derivatives of general formula ##STR1## in their racemic or optically active form, wherein R.sub.1 and R.sub.2, equal or different, are radicals of linear or branched, saturated or monoor poly-unsaturated, aliphatic acids with 1 to 20 C for the preparation of pharmaceutical compositions having an activity as reproductive agent of the nerve fibers in the therapy of human pathologies associated with neuronal damages, more particularly in the therapy of peripheral neuropathies, of cerebrovascular diseases, of cerebral level traumas and of chronic neurodegenerative diseases.

Abstract: A method for treating or preventing neuronal injury in a mammal, comprising the step of administering in vivo a therapeutically effective amount of a long-chain fatty alcohol having from about 23 to about 29 carbon atoms or prodrug esters thereof. Also disclosed are pharmacological compositions containing from 0.01 mg/kg to about 20 mg/kg of the fatty alcohol. The method and compositions are useful in: treating traumatic injury, chemical injury and injury due to disease; promoting and accelerating recovery of behavioral function after such injury; preventing neuronal injury or death; improving training and memory functions; and protecting neurons against injury.

Abstract: The bis-homotris compounds 4-amino-4-[1-(3-hydroxypropyl)]-1,7-heptanediol and 4-[1-(3-aminopropyl)]-4-[1-(3-hydroxypropyl)]-1, 7-heptanediol, and organic synthetic methods for their preparation are described. Unique multifunctional aminotriols, as well as their percursors, quaternary nitroalkanes are disclosed as building blocks for unimolecular micelles, as well as new series of cascade polymers. The quaternary nitro compounds which are disclosed allow the synthesis of a new aminotriol containing a quaternary carbon.

Abstract: The invention discloses a method for inactivating infectious agents in a patient's blood in vivo. The method involves adminstering to the patient a non-toxic, infectious agent inactivating amount of a mixture of oxygen and ozone. The mixture is preferably administered via rectal insufflation or via authohemotherapy.

Abstract: 1-Azabutadienes of the formula ##STR1## where R.sup.1 and R.sup.2 are each phenyl, biphenyl, naphthyl or pyridyl, and these radicals may be substituted, or are each alkyl which is unsubstituted or substituted, R.sup.3 is substituted or unsubstituted phenyl or a radical OR.sup.4, where R.sup.4 is hydrogen, alkyl or an aromatic or aliphatic acyl group, or R.sup.3 is a radical NHR.sup.5, where R.sup.5 is hydrogen, substituted or unsubstituted phenyl, or the carbamide group, and fungicidal agents containing these compounds.

Abstract: A process for the preparation of amines of the formula ##STR1## in which R.sup.1 is the radical H.sub.2 N-CH.sub.2 and R.sup.2 is hydrogen, or R.sup.1 and R.sup.2 together form a bridging group --CH.sub.2 --, by reacting 1,3,6-tricyanohexane at elevated temperature and pressure with hydrogen in contact with a catalyst containing, in addition to cobalt oxide, and oxide of an alkali metal, an oxide of an alkaline earth metal, an oxide of a rare earth or an oxide of scandium or yttrium.

Abstract: A carrier latex for use as a diagnostic reagent, comprising a suspension of particles of a copolymer of ethylene and an .alpha.,.beta.-ethylenically unsaturated carboxylic acid, a salt of an .alpha.,.beta.-ethylenically unsaturated carboxylic acid or a mixture thereof, having an aromatic vinyl compound grafted thereto, the particles possessing a carboxyl group on the surface thereof, can be used in immuno-serological diagnosis utilizing antigen-antibody reaction, while markedly reducing nonspecific agglutination which undesirably occurs in the prior art and increasing the sensitivity of specific agglutination, and is best suited for application to an immuno-serological diagnosis system relying on an optical measurement.

Abstract: Discrete tert-amine oxides, including non-hygroscopic tert-amine oxide dihydrates, are prepared by (A) reacting a concentrated aqueous hydrogen peroxide with a tert-amine corresponding to the formula RR'R"N in which R is a primary alkyl group containing 8-24 carbons; R' is methyl, ethyl, or 2-hydroxyethyl; and R" is independently selected from methyl, ethyl, 2-hydroxyethyl, and primary alkyl groups containing 8-24 carbons in a reaction mixture which is maintained stirrable throughout the reaction by the use, at least during the latter part of the reaction, of an organic solvent which solubilizes the reaction mixture at the reaction temperature but permits precipitation of the tert-amine oxide at a lower temperature and (B) adjusting the water content of the product, if necessary, to achieve a water/tert-amine oxide mol ratio not higher than about 2.1/1 before recovering the tert-amine oxide.

Abstract: Novel magnetic resonance imaging agents and methods which utilize complexes of paramagnetic ions with alkoxyalkylamide derivatives of diethylenetriaminepentaacetic acid ("DTPA") or ethylenediaminetetraacetic acid ("EDTA"). These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. The complexes are represented by the following formula: ##STR1## wherein A is --CH.sub.2 CH.sub.2 -- or ##STR2## and M.sup.+z is a paramagnetic ion of an element with an atomic number of 21-29, 42-44 or 58-70, and a valence, Z, of 2 or 3; the R groups may be the same or different and are selected from the group consisting of -O.sup..crclbar. and lower alkoxyalkylamino groups having from 2 to about 6 carbon atoms, wherein the number of R groups -O.sup..crclbar. equals Z and the remaining R groups are lower alkoxyalkylamino, equal to 4-Z when A is --CH.sub.2 CH.sub.

Abstract: There is provided a method of generating enhanced images of the human or non-human animal body, for example for use in medical diagnosis, which involves administering to the body a positive MRI contrast agent which is body tissue- or body duct-specific following the particular mode of administration and a negative MRI contrast agent which preferably also is body tissue- or body duct-specific. Thereafter a magnetic resonance image is generated of a part of the body containing the negative and positive contrast agents or their paramagnetic, ferromagnetic or superparamagnetic biodegradation products. Contrast media suitable for use in this new image generating method are also provided.

Abstract: A sulpholene compound and more particularly 4,4-dimethyl-2,2-dioxo-1,2,4,5,6,7-hexahydro-benzo[c]thiophene. These compounds are prepared by bringing myrcene sulphone into contact with a strong acid. The compounds of the present invention can be used as synthesis intermediates in the preparation of vitamin A.

Abstract: Guanidines I ##STR1## (A=C.sub.5 -C.sub.12 -cycloalkyl which may bear up to three further substituents; benzyl substituted in the para-position; R.sup.1, R.sup.2, R.sup.3 =H, C.sub.1 -C.sub.4 -alkyl; R.sup.4 -C.sub.5 -C.sub.18 -alkyl which may be interrupted by oxygen, C.sub.5 -C.sub.18 -alkenyl, C.sub.4 -C.sub.18 -alkynyl or phenyl-C.sub.1 -C.sub.6 -alkyl, and these groups may bear up to three further substituents and the phenyl moiety of the phenylalkyl may additionally bear a phenoxy group or up to three C.sub.2 -C.sub.4 -alkenyl, C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.6 -alkyl or haloalkyl groups, C.sub.5 -C.sub.6 -cycloalkyl-C.sub.1 -C.sub.8 -alkyl, where the ring may bear up to three further substituents; A=benzyl and R.sup.4 =C.sub.3 -C.sub.4 -alkyl which may be interrupted by oxygen, or C.sub.4 -alkenyl, both of which may bear up to three further substituents; R.sup.3 +R.sup.4 =C.sub.5 -C.sub.

Abstract: Novel 1-phenylakyl-3-phenylurea derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 is an alkyl group of 1 to 8 carbon atoms, an alkoxy group of 1 to 5 carbon atoms or a halogen atom, R.sup.2 is an alkyl group of 1 to 15 carbon atoms, each of R.sup.3 and R.sup.4 is independently an alkyl group of 1 to 5 carbon atoms, m is an integer of 1 to 3, and n is 0 or 1, are provided.The compounds are potent in reducing the cholesterol level in serum, and useful for treating hyperlipemia and atherosclerosis.

Abstract: Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12;Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group;R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients.The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

Abstract: A process for the hydrogenation of halogenonitro-aromatic compounds wherein said compounds are contacted with a nickel-, cobalt- or iron-based catalyst, preferably Raney nickel, and hydrogen in the presence of a sulfur-containing compound. Preferably, the sulfur-containing compound is a sulfoxide or sulfone, and the molar ratio of the sulfur-containing compound to the catalyst ranges from about 1:1 to 10:1.

Abstract: The compounds disclosed are 1-R'-4-RS-piperidines in which R' and R, which are different, may each represent: (1) (alkoxybenzyl)-alkyl or -alkenyl, or (2) (optionally-substituted chromanyl-, thiochromanyl-, chromenyl- or thiochromenyl)-alkyl or -alkenyl. The compounds are useful in the treatment of disorders associated with tissue ischaemia and of peripheral vascular disorders or in the treatment of disorders in which lipid peroxidation plays an initiating and/or aggravating role. A typical disclosed compound is: 4-(2,3,4-tirmethoxybenzylthio)-1-(3,5-di- tert-butyl-4-hydroxybenzyl)piperidine. ,3,4-trimethoxybenzylthio)-1-(3,5-di-tert-butyl-4-hydroxybenzyl)piperidine .

Abstract: Aromatic diamines, such as toluenediamine, are alkylated in the ortho position by heating the diamine in the presence of an aluminum alloy, aluminium chloride and, optionally, zinc, and then reacting with an alkene at elevated temperatures and pressures.

Abstract: The present invention provides methods and compositions for measuring glucose tolerance in a subject. The methods are useful in a variety of contexts, such as in the diagnosis of diabetes in both human and animal subjects, in assessing gastric emptying times, and even in the diagnosis of insulin resistance. It is proposed that the methods of the present invention will prove to be of particular use in the mass screenings of population, e.g., in screening for type II diabetes mellitus, due to its simplicity and reproducibility. The method is even adaptable to simple finger stick analysis. The invention method includes the use of a potable beverage containing a low total loading dose of glucose in a low osmolar solution. The oral glucose solutions of the present invention empty rapidly from the stomach, thereby eliminating the nausea and vomiting typically associated with oral glucose tolerance tests.